To date, Affimed has incorporated anti-CD16a scFv into various NK cell engager constructs (ROCK® platform) to create Immune Cell Engagers (ICE®) targeting tumor-associated antigens (TAAs) such as EGFR (47), BCMA (48, 49), and CD200 (48). This evidence concerns the gene FCGR3A and neoplasm.